Schrodinger Inc represents a set of core values and a strong corporate philosophy. The company focuses on delivering innovative solutions in the field of computational chemistry and advancing drug discovery and materials science. Schrodinger Inc believes in a multidisciplinary approach, combining scientific expertise with cutting-edge technology to empower researchers and accelerate scientific breakthroughs. With a commitment to collaboration, integrity, and excellence, Schrodinger Inc aims to transform the way pharmaceutical and biotechnology industries approach research and development. By harnessing the power of physics-based simulations and computational models, Schrodinger Inc strives to revolutionize drug discovery and contribute to the advancement of human health.

Schrodinger Inc is primarily present worldwide, with a strong presence in North America, Europe, and Asia. The company's global reach allows it to serve customers and collaborate with partners across borders. Schrodinger Inc's diverse international presence helps foster innovation and the development of cutting-edge computational tools for drug discovery and materials science.

Schrodinger Inc, a renowned company specializing in computational drug discovery, has achieved significant milestones since its inception. The company has developed innovative software solutions and platforms, including the widely acclaimed Schrodinger Suite, which revolutionizes drug discovery processes. Schrodinger Inc has collaborated with prominent pharmaceutical companies, accelerated drug discovery initiatives, and contributed to the development of breakthrough therapies. With its cutting-edge technologies and expertise, the company has successfully advanced multiple drug discovery programs, addressing critical diseases and meeting the evolving needs of the pharmaceutical industry. Schrodinger Inc continues to pave the way in computational chemistry, providing valuable solutions for drug designers and researchers worldwide.

Schrodinger Inc is a renowned chemical simulation and computational drug discovery company. Established in 1990, it has been a pioneer in utilizing physics-based algorithms to accelerate the discovery and development of novel drugs. With a strong focus on research and technology innovation, Schrodinger Inc has emerged as a leader in the field, providing cutting-edge solutions to leading pharmaceutical and biotechnology companies worldwide. By leveraging advanced computational techniques, including molecular dynamics simulations and quantum mechanics, the company enables scientists to gain valuable insights into drug-target interactions, leading to the identification of potential therapeutics. Schrodinger Inc's rich history and expertise make it a trusted partner in accelerating the drug discovery process.

The main competitors of Schrodinger Inc in the market are companies like OpenEye Scientific Software, BioSolveIT, and Chemical Computing Group.

Schrodinger Inc is primarily active in the pharmaceutical and biotechnology industries.

The business model of Schrodinger Inc revolves around computational drug discovery. As a leading company in the field, Schrodinger Inc integrates physics-based simulations and machine learning to facilitate faster and more efficient drug development. By leveraging their innovative software platforms, such as Schrodinger Suite, the company enables biopharmaceutical companies to optimize drug discovery and development processes. Schrodinger Inc's approach allows for the generation of highly accurate computational models of drug-target interactions, aiding in the identification of promising drug candidates. With a strong focus on collaboration and scientific expertise, Schrodinger Inc continues to offer valuable solutions for the pharmaceutical industry.

P/E odnos Schrodinger iznosi -8,19.

KUV kompanije Schrodinger iznosi 6,91.

AlleAktien kvalitativni skor za Schrodinger je 3/10.

očekivana Schrodinger promet je 214,03 mil. USD.

Dobit očekivana Schrodinger je -180,56 mil. USD.

Schrodinger Inc. is a biomedical company based in the United States that specializes in using computer simulations for the development of drugs and chemicals. The company was founded in 1990 by Dr. William L. Jorgensen and is headquartered in New York City. Schrodinger Inc.'s business model is based on the development of simulation software used to accelerate the drug development process, as well as the development of pesticides and other chemicals. The company offers software and services in the fields of medicinal chemistry, materials science, biology, and toxicology. Some of its software products include the Schrödinger Suite, a leading package for molecular simulations and modeling. In addition, the company offers a cloud-based platform called LiveDesign, which allows customers to collaborate with the Schrodinger team securely. Through this platform, users can access data and models in real-time to make faster decisions and achieve multiple goals in shorter timeframes. In the field of drug development, Schrodinger Inc. also offers compute-based services. The company provides its customers with a data-driven approach to identify drug candidates and optimize their pharmacological properties, allowing for faster identification of active ingredients and saving time and money. Additionally, Schrodinger Inc. is capable of delivering its software and services as cloud-based platforms to customers in the biotechnology industry who have limited IT resources. Customers can utilize a private cloud to host their own data and applications, gaining access to a scalable and flexible infrastructure that can quickly and efficiently respond to industry demands. With its innovative and effective technology supporting drug development, Schrodinger Inc. has established itself as a trusted provider of computer-based solutions in the pharmaceutical and biotechnology industries. With a strong focus on research and development, the company remains at the forefront of the industry and is well-positioned to continue growing and expanding.

Schrodinger isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Schrodinger trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Schrodinger je US80810D1037.

WKN od Schrodinger je A2PY7M.

Oznaka za praćenje akcija kompanije Schrodinger je SDGR.

U poslednjih 12 meseci, Schrodinger je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Schrodinger će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Schrodinger trenutno iznosi .

Schrodinger isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Schrodinger je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Schrodinger se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Schrodinger od 19. 9. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 19. 9. 2024..

Isplata poslednje dividende izvršena je 19. 9. 2024..

U godini 2023 kompanija Schrodinger je isplatila 0 USD kao dividende.

Dividende od Schrodinger se isplaćuju u USD.